Independent prescribing is no longer a niche extra that a handful of clinical pharmacists carry. It is becoming the default. From 2026, pharmacists joining the GPhC register are automatically annotated as independent prescribers when they have fully met the 2021 initial education and training standards, passed the registration assessment and met the registration criteria. That single change reshapes what a pharmacist brings to a GP practice, and it raises practical questions about supervision, scope and governance that practices need to answer before, not after, an IP pharmacist starts seeing patients.
This post sets out what an independent prescribing (IP) pharmacist can safely do in primary care, the questions a practice should ask about oversight, and why the model you choose for that clinical work matters as much as the qualification itself.
What independent prescribing actually is
An independent prescriber can assess a patient, reach a clinical decision and prescribe within their own area of competence, without needing a doctor to authorise each item. It is a regulated qualification on top of registration as a pharmacist with the General Pharmaceutical Council (GPhC). Until recently it was an additional course that pharmacists completed after qualifying, often several years into practice. The reform to initial education enables eligible new registrants to receive independent prescriber annotation when they join the register; other pharmacists need the relevant additional training and annotation.
The phrase that matters most is “within their own area of competence”. An IP qualification does not mean a pharmacist can prescribe anything for anyone. A responsible prescriber works inside a defined scope of practice, declines what sits outside it, and refers on. For a practice, the governance question is rarely about the qualification itself. It is whether the scope, supervision and safety nets around that prescribing are clear and documented.
What an IP pharmacist can do in primary care
The strongest fit for independent prescribing pharmacists is structured, protocol-friendly work where they can take real clinical ownership rather than passing every decision back to a GP. In practice that tends to mean:
- Long-term condition management. Reviewing and titrating treatment for conditions such as hypertension, type 2 diabetes, asthma and COPD, against agreed local pathways, and adjusting medicines where the clinical picture supports it.
- Structured medication reviews. Conducting full reviews for patients on multiple medicines, identifying interactions and deprescribing opportunities, and acting on the findings instead of only flagging them. You can read how this works in practice on our clinical medication reviews page.
- High-risk drug monitoring. Managing agreed monitoring work for medicines such as DMARDs, anticoagulants and lithium: tracking recalls, reviewing available results and making or escalating prescribing decisions within the agreed scope. Our high-risk drug monitoring service is built around exactly this kind of closed-loop work.
- Medicines optimisation and switches. Implementing formulary changes, safe therapeutic switches and cost-effective prescribing in line with local medicines optimisation priorities.
- Prescription queries and acute support. Resolving prescribing queries and managing defined minor or self-limiting presentations where a clear pathway exists.
- Prescription signing. Signing prescriptions within their competence, so fewer wait for a GP.
The common thread is that IP lets the pharmacist close the loop. Instead of a GP signing off every change a pharmacist recommends, the pharmacist completes the episode within their competence. That is where the workload benefit shows up, because it removes a layer of duplicated clinical effort.
The supervision and governance questions to ask
The qualification removes the requirement for a doctor to authorise each prescription. It does not remove the need for clinical oversight. Good IP practice depends on structure around the prescriber, and that structure is what a GP practice, PCN or ICB should interrogate before any prescribing starts.
Practical questions worth asking:
- Is the scope of practice written down? A clear, documented scope tells everyone what the pharmacist will and will not prescribe, and how that scope changes as competence grows.
- Who provides clinical supervision? Even an experienced IP needs a named supervising clinician or clinical lead, access to advice on complex cases, and a route to escalate. A newly qualified IP needs this more, not less.
- How is prescribing reviewed? Peer review of prescribing decisions, audit of outcomes and regular case discussion are what keep prescribing safe over time. One-off competence at qualification is not the same as sustained safe practice.
- How are incidents handled? There should be a clear process for significant events, prescribing safety alerts and learning, sitting inside the practice’s existing clinical governance.
- What happens to continuity if a person leaves? If oversight and prescribing knowledge live in one individual, their departure leaves a gap. The arrangement should not depend on a single person.
Professional regulation and service registration are different questions. Pharmacists are regulated by the GPhC. Whether a provider needs CQC registration depends on the activities delivered and who is responsible for carrying them on, including the subcontracting arrangement. Confirm that position and the responsibilities of each organisation before the service starts; work delivered in a practice is not automatically covered by its registration.
Why the delivery model shapes how safely IP works
An independent prescriber is only as safe as the system around them. A practice can recruit an IP pharmacist directly, and many do. But that puts the full weight of supervision, scope-setting, peer review, audit and continuity on the practice itself, on top of everything else partners already carry. When the prescriber is newly qualified, that load is heavier still.
This is where a managed clinical service differs from simply having a prescriber in the building. Virtual Pharmacist provides a fully managed, remote clinical pharmacy service delivered inside your own clinical system, EMIS, SystmOne, Vision or Medicus, by GPhC-registered pharmacists and pharmacy technicians. This is not about gaining a person on site. Our pharmacists are professionally accountable for their own clinical decisions and any prescriptions they sign. Virtual Pharmacist is accountable for the service we deliver, including its clinical governance, supervision and quality assurance. The commissioning practice or organisation retains its own clinical and regulatory responsibilities.
In an IP context that means the scope of practice, the supervision arrangements, the peer review of prescribing decisions and the audit of outcomes are part of the service, not a separate burden the practice has to build and maintain. Our clinical governance and data security framework, including NHS Data Security and Protection Toolkit compliance, Cyber Essentials and HSCN, sits behind the clinical work. If you are weighing up a managed service against recruiting or using agency staff, the distinction matters: a managed service holds the governance and continuity, rather than handing you an individual and the oversight that comes with them.
Continuity is part of the same picture. Safe prescribing depends on consistent oversight over months and years, not a competent start that erodes when an individual moves on. A managed service is designed to hold that consistency at the level of the service, not the individual.
How this fits PCN and ICB priorities
At PCN level, independent prescribing is central to making clinical pharmacy roles deliver value rather than sit as recommendation engines. An IP who can own long-term condition reviews and high-risk monitoring frees GP time and supports the network’s wider priorities. You can see how we support networks on our PCN management support and ARRS support pages.
For ICBs focused on medicines optimisation and safe prescribing at scale, the governance question is the same one a single practice faces, multiplied across many sites. A consistent, managed approach to IP oversight is far easier to assure than a patchwork of locally held arrangements. As more pharmacists qualify with independent prescriber annotation, practices need clear arrangements for scope, support and oversight.
Sources
GPhC independent prescriber education guidance; GPhC guidance for pharmacist prescribers; CQC scope of registration.
Frequently asked questions
What is an independent prescribing pharmacist?
An independent prescribing pharmacist is a GPhC-registered pharmacist who also holds the independent prescriber qualification. They can assess a patient, make a clinical decision and prescribe within their own defined area of competence, without a doctor authorising each item. They are expected to work to a clear scope of practice and refer anything outside it.
Is independent prescribing becoming standard for pharmacists?
Yes. From 2026, pharmacists joining the GPhC register are automatically annotated as independent prescribers when they have fully met the 2021 initial education and training standards, passed the registration assessment and met the registration criteria. Pharmacists who qualified earlier may still hold IP as an additional qualification gained later. Over time the share of pharmacists who can prescribe will increase considerably.
Does an IP pharmacist still need supervision in a GP practice?
The qualification removes the need for a doctor to sign off each prescription, but it does not remove the need for clinical oversight. Safe IP practice relies on a documented scope of practice, named clinical supervision, peer review of prescribing, audit of outcomes and a clear escalation route. This is more important, not less, for a newly qualified prescriber.
Who is responsible for the work, the practice or the pharmacist?
Pharmacists remain professionally accountable for their own practice. The responsibilities of the commissioning organisation and service provider, including clinical governance, escalation, indemnity and any CQC registration requirement, must be clear for the specific service arrangement. Virtual Pharmacist provides governance and quality assurance for the work it delivers.
How does a managed service help with IP governance?
A managed clinical service builds the scope-setting, supervision, peer review, audit and continuity into the service itself, so the practice never has to construct and maintain them alone. For independent prescribing, where consistent oversight over time is what keeps prescribing safe, that structure is the difference between a qualification on paper and prescribing that is safe in practice.
If your practice, PCN or ICB is thinking about how independent prescribing fits into your clinical pharmacy work, and how to put the right governance around it, contact Virtual Pharmacist to discuss your needs. We will talk through what a managed, remote service can do for you and how we hold the clinical oversight that makes IP work safely.
